Advertisement

Topics

Companies Related to "Innovent Presents Clinical Data Anti Antibody Sintilimab Patients" [Most Relevant Company Matches] RSS

13:27 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Innovent Presents Clinical Data Anti Antibody Sintilimab Patients" found in our extensive corporate database of over 50,000 company records.

Showing "Innovent Presents Clinical Data Anti Antibody Sintilimab Patients" Companies 1–25 of 10,000+

Relevant

Synergys Biotherapeutics

Synergys is an early stage company developing multifunctional anti-vascularization antibody drugs targeting VEGF-alternative pathways. The Company’s most advanced product candidate, Anti-EGFR‐TAP (SYN001) was derived from its platform technology termed A‐TAP (Antibody-Targeted Anti-Vascularization Payload). SYN001 is currently in preclinical ...


KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc., a U.S. based, private monoclonal company, uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. The company has multiple programs that have been in seven Phase 1 or 2 clinical trials in the last few years. KB001 is a PEGylated monoclonal antibody fragmen...

Arcus Biosciences, Inc.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an an...


Shared Health

With Clinical Insight, clinicians can access a practice management tool that presents a broad view of the care delivered across their patient population. Clinical Insight allows practices to generate reports that determine opportunities to provide care for specific groups of patients and ultimately improve outcomes for all patients.

Arch Oncology, Inc.

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative...

Avaxia Biologics, Inc.

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and ...

Emerge Clinical Solutions

Emerge offers unparalleled clinical data support and documentation to medical professionals. Through sophisticated analysis of electronic medical records, Emerge identifies potential inconsistencies within EHR data and presents doctors with patient-specific care-paths per the latest guidelines. Increased efficiency and enhanced risk detection are delivered...

Lpath

Lpath, Inc., headquartered in San Diego, California, is a theranostics company focused on bioactive signaling lipids as targets for treating and diagnosing important human diseases. Lpath's lead product candidate, Sphingomab™, is a monoclonal antibody (mAb) against a validated cancer target, sphingosine-1-phosphate (S1P), and has demonstrated compelling results against six different forms of sol...

A&G Pharmaceutical Incorporated

A&G Pharmaceutical, Inc. (A&G) was incorporated in Delaware on June 6, 2000, as a "C" Corporation, to make use of two proprietary technologies that are unique to the Company. A&G is located in Baltimore, Maryland, and consists of two distinct but integrate divisions: 1) the Pharmaceutical Division and 2) the Monoclonal Antibody Services Division. Pharmaceutical Division Breast cancer is the most ...

OncoResponse

OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fully-human monoclonal antibody being developed for female malignancies. The OncoResponse discovery engine is working to increase the success rate of cancer immunotherapies by ident...

Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates into the clinic, including XmAb...

Geneva Healthcare

Geneva Healthcare is focused on building the leading cardiac device data management suite. The Geneva Healthcare Suite transforms cardiac device data into actionable information for providers, physicians, payers and patients, improving the quality of care while increasing efficiency and lowering costs. The suite’s unique dashboard presents patient data in a ...

ThromboGenics NV and BioInvent International

ThromboGenics is a biotechnology company focused on the discovery and development of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additio...

Peptech Limited

We are an ASX-listed Australian biopharmaceutical company dedicated to developing and providing peptide- and antibody-based therapeutic products for the treatment of diseases in the areas of cancer, inflammation and infection. For more than 20 years, our company has tapped its unique antibody technology and pioneering anti-TNF patents to build a diverse range of high quality biopharmaceutical asse...

HealthCare Pharmaceuticals, Inc.

HealthCare Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel, targeted therapies for the treatment of patients with cancer. DKN-01, our clinical-stage monoclonal antibody, is currently being tested in Phase 1b and Phase 2 clinical trials for patients with DKK1+ esophageal cancer and multiple mye...

monARC Bionetworks

monARC Bionetworks is a healthcare technology company on a mission to modernize the clinical research industry by empowering patients to share their data and participate in research anytime, anywhere. By allowing patients to directly share their data, monARC is creating a new data collaboration economy to transform highly sequential and siloed therapy deve...

Axentis Pharma AG

Axentis Pharma is a Swiss-based pharmaceutical company focused on chronic lung diseases and respiratory related disorders, especially on cystic fibrosis. Axentis Pharma is solely financed by private investors. The company is currently looking for co-development and co-marketing partners in the respiratory arena with the goal to create a competence center for healthcare professionals and patients...

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong financial foundations, good medium term prospects and significant opportunities for growth in the longer term.

Antibody Solutions

Antibody Solutions Inc., based in Palo Alto, California, offers quality antibody development, antibody manufacture and immunoassay development that are optimized for your specific application. We serve biotechnology, diagnostic, and pharmaceutical companies, as well as universities by providing innovative antibody products and services.

Opsona Therapeutics Limited

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Novacea

We are a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. We currently have two clinical-stage oncology product candidates. Our lead product candidate, Asentar™ (DN-101), is in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer, or AIPC, also known as hormone-refractory prostate cancer. ...

MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in monoclonal antibody product development. The company's product development efforts leverage three ...

Serametrix Corporation

Serametrix provides solutions to the problem of monitoring immune response to immunotherapies in clinical trial cancer patients. In partnership with leading institutes Serametrix has developed a suite of immunoassays that monitor anti-tumor immunity in patients enrolled into clinical trials for novel cancer therapies. Serametrix is part owned by the LICR. ...

Acceptys, Inc.

Acceptys is a private biotechnology company focused on the development of human antibody therapies in cancer and infectious diseases. The Company's key strength is its ability to directly leverage the power of the human immune system, which has continually evolved with the specific purpose of preserving health. More specifically, Acceptys can capture thousands of antibodies from strategically targ...

Grid Therapeutics, LLC

Grid Therapeutics is a biotech company based on the innovative platform for discovering and isolating human derived antibodies. Dr Edward F. Patz, Jr, is the co-founder and CEO of Grid, located in Durham, North Carolina. The lead antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. ...


More From BioPortfolio on "Innovent Presents Clinical Data Anti Antibody Sintilimab Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks